Navigation Links
Micromet Added to Russell 3000 Index
Date:6/29/2009

Nycomed. Micromet's licensee Morphotek, a wholly-owned subsidiary of Eisai, is also expected to initiate a first phase 1 clinical trial with Micromet's glycolipid-binding human antibody MT228 for the treatment of melanoma.

Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. A BiTE antibody targeting CEA for the treatment of solid tumors is being developed in collaboration with MedImmune. In addition, Micromet has entered into an option, collaboration and license agreement with Bayer Schering Pharma AG under which Bayer Schering Pharma was granted an exclusive option to license a specified BiTE antibody against an undisclosed solid tumor target. Other BiTE antibodies targeting MSCP, CD33, HER2, EGFR and other targets are in various stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the conduct, timing and results of future clinical trials, and expectations of the future expansion of our product pipeline and collaborations. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do n
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
2. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
3. Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
4. Micromet, Inc. to Host Conference Call and Webcast to Report First Quarter 2009 Financial Results on May 6, 2009
5. Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110
6. Micromet to Present at the Future Leaders in the Biotech Industry Conference on April 2, 2009
7. Micromet Adds Sir Walter Bodmer and Bernard Fox to Its Advisory Panel for BiTE Antibody Therapeutics
8. Micromet to Present Six Posters on Progress of BiTE Antibodies at the Annual Meeting of American Association for Cancer Research
9. Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008
10. Micromet to Present at the Cowen Health Care Conference on March 17, 2009
11. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Bill Jacobs Automotive, a group of car dealerships headquartered ... the Heartland Blood Center and offering free oil change coupons ... place Saturday, Jan. 18 at the Bill Jacobs Cadillac and ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The Bill Jacobs ...
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health ... behavior change technology, today announces that EmblemHealth , ... and wellness company, is now providing the RedBrick Compass ... coaching program, to all of its members. EmblemHealth is ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
... Programs to Include Response Prediction to Ovarian Cancer ... Differentiation of Small Cell From Non-Small Cell Lung Cancer, In Addition, ... Cancer Patients, Which may Serve as the Basis for a Future ... Test ...
... Lead Discovery, COPENHAGEN, June 18 Nuevolution ... drug discovery collaboration with Merck & Co.,Inc., ... to identify novel small molecule leads against several ... uses innovative DNA,labeling to allow fragment-based drug screening ...
... HARTFORD, Conn., June 17 The Connecticut,Technology Council (CTC) ... in,partnership with accounting firm UHY LLP this November, to ... will be,recognized on the basis of revenue growth over ... and minimum revenues of $3 million in,the fourth year., ...
Cached Biology Technology:Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 4Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 5Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc. 2Connecticut Technology Council to Recognize Fast Growing Technology Companies 2
(Date:4/22/2014)... a five-year, $3 million study to determine whether an ... of dissolved organic matter (DOM) through the Connecticut River ... composition and water quality of the watershed and Long ... Foundation,s MacroSystems Biology program, researchers will collect data from ... Canada and runs through five U.S. states, before emptying ...
(Date:4/22/2014)... 2014) Biotechnology scientists must be aware of the ... licensing guidelines, according to a new paper from Rice ... the current issue of the journal Regenerative Medicine ... U.S. Supreme Court ruling in the case Association for ... genes are unpatentable. The court case and rulings garnered ...
(Date:4/22/2014)... Mass. Scientists at the University of Massachusetts Amherst ... Brazil, this week report that they have discovered a ... tributaries of the Negro River in the Amazonia State ... Amherst, with Adlia Nogueira and Jos Antnio Alves-Gomes of ... issue of the journal Proceedings of the Natural ...
Breaking Biology News(10 mins):Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2
... drug has lowered blood sugar levels and inflammation in mice ... be added to the arsenal of drugs used by millions ... The drug consists of a synthetic molecule that stops the ... or MIF. This protein is implicated in a number of ...
... the Australian National University, Research School of Chemistry, has ... Otting is on the editorial board of Springer,s ... Award is granted in recognition of a researcher,s entire ... had a significant impact on their own discipline. The ...
... and the University of Ottawa have identified a promising new ... the leading inherited cause of death in infants and toddlers. ... found that an enzyme called RhoA is overly active in ... can greatly increase survival. The study is published in ...
Cached Biology News:Study points to potential new drug for type 2 diabetes 2Study points to potential new drug for type 2 diabetes 3Study points to potential new drug for type 2 diabetes 4Study opens new avenue for developing treatments for genetic muscle-wasting disease 2
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: